Top Markets
#1 GEKKO GEKKO +52.86%
#2 ADO Protocol ADO Protocol +38.50%
#3 Helium Helium +29.80%
#4 Pons Pons +28.26%
#5 TENDIES TENDIES +23.40%
#6 龙虾 (Lobster) 龙虾 (Lobster) +19.97%
#7 o1.exchange o1.exchange +18.32%
#8 Main Street Yield Main Street Yield +17.48%
#9 Nillion Nillion +16.96%
#10 Giggle Fund Giggle Fund +15.80%
Coin of the day
GEKKO GEKKO
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Clasificación en acciones #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Precio por acción
$9.60
Última sincronización: 2025-05-21
Capitalización bursátil
$1.08B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio OptiNose, Inc. (OPTN)

Categoría

Healthcare
Ingresos de OptiNose, Inc. (OPTN)
Ingresos en Mar 2025 TTM: $81.86M
Según los últimos informes financieros de OptiNose, Inc., los ingresos actuales de la empresa (TTM) son $81.86M. En 2023, la empresa obtuvo unos ingresos de $70.99M una disminución en comparación con los ingresos del año 2022, que fueron de $76.28M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de OptiNose, Inc. desde 2015 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $81.86M 4.64%
2024 $78.23M 10.20%
2023 $70.99M -6.93%
2022 $76.28M 2.18%
2021 $74.65M 51.99%
2020 $49.12M 41.83%
2019 $34.63M 390.18%
2018 $7.07M 0.00%
2017 0.00 -100.00%
2016 $47.50M 55,782.35%
2015 $85.00K 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B 7,977.17%
IN